Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/221118
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Pilot production of SARS-CoV-2 related proteins in plants: a proof of concept for rapid repurposing of indoors farms into biomanufacturing facilities

AutorDiego-Martin, Borja CSIC ORCID; González, Beatriz CSIC ORCID; Vázquez Vilar, Marta; Selma, Sara; Mateos-Fernández, Rubén; Gianoglio, Silvia; Fernández-del-Carmen, Asun CSIC ORCID; Orzáez, Diego CSIC ORCID
Palabras claveCOVID-19
SARS-CoV-2
Nicotiana benthamiana
Plant-made antibody
Plantmade antigen
Biofactories
Synthetic biology
Fecha de publicación13-oct-2020
EditorBioRxiv
ResumenThe current CoVid-19 crisis is revealing the strengths and the weaknesses of the world's capacity to respond to a global health crisis. A critical weakness has resulted from the excessive centralization of the current biomanufacturing capacities, a matter of great concern, if not a source of nationalistic tensions. On the positive side, scientific data and information have been shared at an unprecedented speed fuelled by the preprint phenomena, and this has considerably strengthened our ability to develop new technology-based solutions. In this work we explore how, in a context of rapid exchange of scientific information, plant biofactories can serve as a rapid and easily adaptable solution for local manufacturing of bioreagents, more specifically recombinant antibodies. For this purpose, we tested our ability to produce, in the framework of an academic lab and in a matter of weeks, milligram amounts of six different recombinant monoclonal antibodies against SARS-CoV-2 in Nicotiana benthamiana. For the design of the antibodies we took advantage, among other data sources, of the DNA sequence information made rapidly available by other groups in preprint publications. mAbs were all engineered as single-chain fragments fused to a human gamma Fc and transiently expressed using a viral vector. In parallel, we also produced the recombinant SARS-CoV-2 N protein and its Receptor Binding Domain (RBD) in planta and used them to test the binding specificity of the recombinant mAbs. Finally, for two of the antibodies we assayed a simple scale-up production protocol based on the extraction of apoplastic fluid. Our results indicate that gram amounts of anti-SARS-CoV-2 antibodies could be easily produced in little more than 6 weeks in repurposed greenhouses with little infrastructure requirements using N. benthamiana as production platform. Similar procedures could be easily deployed to produce diagnostic reagents and, eventually, could be adapted for rapid therapeutic responses.
Versión del editorhttps://doi.org/10.1101/2020.10.13.331306
URIhttp://hdl.handle.net/10261/221118
DOI10.1101/2020.10.13.331306
Aparece en las colecciones: (PTI Salud Global) Colección Especial COVID-19
(IBMCP) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Pilot production of SARSCoV2 related proteins in plants.pdf1,11 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

Page view(s)

232
checked on 28-mar-2024

Download(s)

242
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Este item está licenciado bajo una Licencia Creative Commons Creative Commons